A comparative trial of azapropazone and ketoprofen in the treatment of acute backache.
A double-blind trial of azapropazone (300 mg. 4-times daily) and ketoprofen (50 mg. 4-times daily) was carried out in 50 patients with acute backache sufficiently severe to necessitate hospital admission. Of 39 patients who completed the full 3-weeks' study period, 18 preferred azapropazone therapy, 10 preferred ketoprofen, and 11 showed either preference for the intermediate placebo period or no preference at all. Ten patients suffered from sufficiently severe side-effects with ketoprofen to necessitate their withdrawal from the trial. There were no similar episodes of withdrawal occurring during the azapropazone period.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001032:Apazone / Q000009:adverse effects / Q000627:therapeutic use*; D001416:Back Pain / Q000188:drug therapy*; D001577:Benzophenones / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007660:Ketoprofen / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014227:Triazines / Q000627:therapeutic use*
D001577:Benzophenones; D014227:Triazines; D007660:Ketoprofen; D001032:Apazone